Skip to main content


You are viewing the new article page. Let us know what you think. Return to old version

Poster presentation | Open | Published:

Efficacy and safety of anti-TNF agents in patients with enthesitis related arthritis


Approximately 5–15% of patients with juvenile idiopathic arthritis belong to a subcategory of enthesitis related arthritis (ERA), which is strongly associated with HLA-B27 and male gender. Recent investigations have suggested markedly low discontinuation rates of anti-tumour necrosis factor (anti-TNF) agents in those with ERA, in whom reports on long-term efficacy and safety of anti-TNFs are still few.

Patients and methods

Based on Finnish register on biologic agents (ROB-FIN) in children, assessment of efficacy was available in 12 male patients with ERA, mean age being 13.6 years at anti-TNF onset (range 8.9–17.3), mean duration of ERA 2.6 years (range 0.2–6.3), and mean follow-up on anti-TNFs 18.5 months (range 6.0–70). All patients were receiving their first course of anti-TNF agents; 7 infliximab, 4 etanercept, and 1 adalimumab.


At 3 months, 100% achieved ACR Pediatric 30% improvement (ACR Pedi 30), 83% ACR Pedi 50, 83% ACR Pedi 70, and 17% ACR Pedi 100. At 6 months, these rates were 100%, 100%, 83%, and 17%; and at 12 months 100%, 100%, 83%, and 17%. Three patients achieved ARC Pedi 70 at 24 months, and one also at 60 and at 70 months. No-one discontinued anti-TNFs due to adverse events (AEs) or inefficacy. Two patients, one on etanercept and another on infliximab, discontinued the therapy due to clinical remission at 70 and 26 months, respectively. The former relapsed within 6 weeks. Per 100 patient-years, 7.7 AEs and 0.45 serious AEs occurred.


Anti-TNF agents seem to be safe and highly effective in ERA.

Author information

Correspondence to P Tynjälä.

Rights and permissions

Reprints and Permissions

About this article


  • Public Health
  • Adverse Event
  • Arthritis
  • Male Patient
  • Infliximab